Endocrinology

Trial of Radiotherapy in Combination With TTI-101 in Patients With Borderline Resectable Pancreatic Cancer

Conditions: Pancreatic Cancer
Interventions: Drug: TTI-101
Sponsors: University of Colorado, Denver; Tvardi Therapeutics, Incorporated
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 30, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Efficacy and Safety of SGLT2 Inhibitor Therapy in Overweight and Obese Subjects With Cystic Fibrosis-related Diabetes: a Pilot Study

Conditions: Cystic Fibrosis-related Diabetes; Cystic Fibrosis
Interventions: Drug: Empagliflozin; Other: Placebo Control
Sponsors: Amir Moheet
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 30, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
A Study to Test Whether BI 456906 Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

Conditions: Obesity; Diabetes Mellitus, Type 2
Interventions: Drug: BI 456906; Drug: Placebo
Sponsors: Boehringer Ingelheim
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 30, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Continuous Glucose Monitor for Mayo Clinic Advanced Care at Home Patients

Conditions: Diabetes Mellitus
Interventions: Device: Continuous Glucose Monitor Dexcom G6 PRO
Sponsors: Mayo Clinic
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 30, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.

Conditions: Adrenoleukodystrophy
Interventions: Drug: MIN-102; Drug: Placebos
Sponsors: Minoryx Therapeutics, S.L.
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 30, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors

Conditions: Ovarian Cancer; Fallopian Tube Adenocarcinoma; Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma; Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube Mucinous Adenocarcinoma; Fallopian Tube Serous Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fallopian Tube Undifferentiated Carcinoma; Malignant Ovarian Brenner Tumor; Ovarian Adenocarcinoma; Ovarian Carcinosarcoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Adenocarcinoma; Ovarian Seromucinous Carcinoma; Ovarian Serous Adenocarcinoma; Ovarian Transitional Cell Carcinoma; Ovarian Undifferentiated Carcinoma; Primary Peritoneal Serous Adenocarcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Transitional Cell Carcinoma
Interventions: Other: Exercise Counseling; Other: Aerobic Exercise; Other: Physiological Support; Other: Quality-of-Life Assessment; Other: Questionnaire Administration; Other: Best Practice
Sponsors: University of Washington; National Cancer Institute (NCI)
Terminated

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 30, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2; Neuroendocrine Tumor of Pancreas
Interventions: Drug: [212Pb] VMT-α-NET; Diagnostic Test: [203Pb] VMT-α-NET SPECT/CT
Sponsors: David Bushnell; Holden Comprehensive Cancer Center; National Cancer Institute (NCI); Perspective Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 29, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Cell-Free DNA CHIP for Diagnosing Cancer

Conditions: Cancer of Pancreas
Interventions: Other: Non-Human Subject Research study.
Sponsors: University of Central Florida
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 29, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Conditions: Ductal Carcinoma in Situ
Interventions: Drug: Tamoxifen; Drug: Exemestane; Drug: Letrozole; Drug: Anastrazole; Drug: Testosterone + Anastrazole; Drug: Elacestrant; Drug: Z-endoxifen
Sponsors: QuantumLeap Healthcare Collaborative
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 29, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Conditions: Recurrent Ovarian Cancer
Interventions: Drug: CPI-0209; Drug: carboplatin
Sponsors: Lan Coffman; MorphoSys AG; National Cancer Institute (NCI)
Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 29, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine